 The Menarini Group and Radius Health Inc NASDAQ: RDUS have announced topline results from the EMERALD Phase 3 study evaluating elacestrant as second- or third-line monotherapy in ERHER2- advancedmetastatic breast cancer patients. There were two primary endpoints: progression-free survival PFS in the overall population and PFS in patients with tumors harboring estrogen receptor 1 ESR1 mutations. 